The new findings certainly point in this direction. For years, the pharmaceutical market has relied on minoxidil and finasteride — the only FDA-approved drugs for treating androgenic alopecia.

Spironolactone is usually only prescribed when other treatments, such as minoxidil, don’t work. A 2023 review of research found that about 43% of people with female pattern hair loss noticed an ...